menu
    • menu
    [{"orgOrder":0,"company":"Step Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"STP938","moa":"CTPS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Step Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Step Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Step Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Step Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"STP938","moa":"CTPS1","graph1":"Oncology","graph2":"Phase I","graph3":"Step Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Step Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Step Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Step Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"STP938","moa":"CTPS1","graph1":"Hematology","graph2":"Phase I","graph3":"Step Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Step Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Step Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Step Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"STP938","moa":"CTPS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Step Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Step Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Step Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Step Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"STP938","moa":"CTPS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Step Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Step Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Step Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Step Pharma","sponsor":"Hadean Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"STP938","moa":"CTPS1","graph1":"Oncology","graph2":"Preclinical","graph3":"Step Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Step Pharma \/ Hadean Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Step Pharma \/ Hadean Ventures"},{"orgOrder":0,"company":"Step Pharma","sponsor":"V-Bio Ventures | Pontifax | Bpifrance| Kurma Partners| Hadean Ventures | Sunstone Life Science Ventures| Inserm Transfert Initiative","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Series C Financing","leadProduct":"Dencatistat","moa":"CTPS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Step Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Step Pharma \/ V-Bio Ventures | Pontifax | Bpifrance| Kurma Partners| Hadean Ventures | Sunstone Life Science Ventures| Inserm Transfert Initiative","highestDevelopmentStatusID":"7","companyTruncated":"Step Pharma \/ V-Bio Ventures | Pontifax | Bpifrance| Kurma Partners| Hadean Ventures | Sunstone Life Science Ventures| Inserm Transfert Initiative"}]

    Find Clinical Drug Pipeline Developments & Deals by Step Pharma

    Menu

    Step Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Step Pharma

                            France arrow
                            AAPS
                            Not Confirmed

                            Step Pharma

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dencatistat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : V-Bio Ventures | Pontifax | Bpifrance| Kurma Partners| Hadean Ventures | Sunstone Life Science Ventures| Inserm Transfert Initiative

                            Deal Size : $44.2 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Step Pharma Completes €38M Series C Financing

                            Details : The Series C financing will support the development of a lead product targeting CTPS1 in essential thrombocythaemia.

                            Product Name : STP938

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 15, 2025

                            Lead Product(s) : Dencatistat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : V-Bio Ventures | Pontifax | Bpifrance| Kurma Partners| Hadean Ventures | Sunstone Life Science Ventures| Inserm Transfert Initiative

                            Deal Size : $44.2 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Step Pharma

                            France arrow
                            AAPS
                            Not Confirmed

                            Step Pharma

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STP938

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia

                            Details : STP938 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Thrombocythemia, Essential.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 22, 2025

                            Lead Product(s) : STP938

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Step Pharma

                            France arrow
                            AAPS
                            Not Confirmed

                            Step Pharma

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STP938

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of STP938 in Advanced Solid Tumours

                            Details : STP938 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 07, 2024

                            Lead Product(s) : STP938

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Step Pharma

                            France arrow
                            AAPS
                            Not Confirmed

                            Step Pharma

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STP938

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in a Phase...

                            Details : STP938 is a first-in-class oral cancer therapeutic that specifically inhibits nucleotide synthesis and the enzyme cytidine triphosphate synthase 1 (CTPS1) in particular, originally identified as an essential gene for lymphocyte proliferation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 24, 2022

                            Lead Product(s) : STP938

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Step Pharma

                            France arrow
                            AAPS
                            Not Confirmed

                            Step Pharma

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STP938

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Step Pharma Progresses into Oncology Clinical Trials with STP938, the World’s Most Advanced CTPS1 Inhibitor

                            Details : Promising pre-clinical data demonstrated strong synergistic cancer-killing potential of STP938 in combination with the emerging drugs targeting the DNA damage response pathway (e.g. ATR, WEE1, CHEK1) for solid tumours.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 28, 2022

                            Lead Product(s) : STP938

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Step Pharma

                            France arrow
                            AAPS
                            Not Confirmed

                            Step Pharma

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STP938

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

                            Details : STP938 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 18, 2022

                            Lead Product(s) : STP938

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Step Pharma

                            France arrow
                            AAPS
                            Not Confirmed

                            Step Pharma

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STP938

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Hadean Ventures

                            Deal Size : $42.3 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Step Pharma Raises Funds Through Series B Round to Advance Cancer Drugs

                            Details : The proceeds will be used to advance Step Pharma’s lead proprietary CTPS1 inhibitor, STP938, into clinical development for the treatment of T-cell malignancies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 23, 2021

                            Lead Product(s) : STP938

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Hadean Ventures

                            Deal Size : $42.3 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth